Roche – Group report and key figures
A report presented through summary slides of group's operations
Detailed history of financial performances between 2020 and 2024
An overview of the group's major business strategies
A medium-term outlook for opportunities and threats
650 €
WHAT IS THE GROUPS' FINANCIAL SITUATION ?
The financial indicators presented in this report include: consolidated revenue, consolidated EBIT and EBIT ratio, consolidated net profit and net profit rate, R&D expenditure and ratio, sales by segment and by region, profitability, liquidity and solvency ratios, free cash flow and capital expenditure.
WHAT ARE THE GROUP'S STRATEGIC PRIORITIES ?
From blockbuster erosion to portfolio renewal
Capitalise on external innovation to enter strategic segments
Lever diagnostics and digital integration
WHAT ARE THE GROUP'S STRENGTHS AND WEAKNESSES ?
Through a SWOT analysis, this report also provides an overview of the group's strengths (leading global pharma player with strong brand and broad geographical presence, etc.) and weaknesses (loss of exclusivity on key biologics (Avastin, Herceptin, Rituxan), etc.).
Detailed plan
Presentation
Segments
SWOT
Related reports
ACCESS THE REPORT
